- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00021229
Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma
A Phase I/II Trial Of STI571 In Children With Newly Diagnosed Poor Prognosis Brainstem Gliomas And Recurrent Intracranial Malignant Gliomas
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Determine the maximum tolerated dose (MTD) of imatinib mesylate after completion of radiation in children with newly diagnosed poor prognosis brainstem gliomas. (Phase I, strata I closed to accrual as of 5/28/04.) II. Determine the maximum tolerated dose (MTD) of imatinib mesylate in children with recurrent high-grade intracranial glioma stratified according to the use of enzyme-inducing anticonvulsant drugs (EIACDs). (Phase I, strata IIA and IIB closed to accrual as of 8/15/03 and 8/15/04, respectively) III. Determine the safety and efficacy of this drug in patients with newly diagnosed diffuse intrinsic brainstem gliomas. (Phase II)
SECONDARY OBJECTIVES:
I. Explore neuroimaging and biological correlatives of therapeutic activity of this regimen in these patients. (Phase I, all strata closed to accrual as of 8/15/04) II. Determine the pharmacokinetics of these regimens in these patients overall and by enzyme-inducing anticonvulsant drugs (EIACDs) (Phase I, all strata closed to accrual as of 8/15/04.) III. Estimate the progression-free survival (PFS) and overall survival (OS) of newly diagnosed diffuse intrinsic brainstem gliomas treated with this drug. (Phase I and II)
OUTLINE: This is a phase I dose-escalation, multicenter study followed by a phase II. Patients are stratified according to tumor type (newly diagnosed intrinsic brainstem glioma vs recurrent/refractory intracranial high-grade glioma). Patients in stratum II (phase I only) are further stratified according to concurrent use of enzyme-inducing anticonvulsant drugs (EIACDs) (yes vs no). Patients are assigned to one of three strata in the phase I study.
Phase I
- Stratum I (newly diagnosed brainstem glioma): Patients undergo radiotherapy once daily five days a week for 6 weeks. Beginning 1-3 weeks after completion of radiotherapy, patients without evidence of intratumoral bleed receive oral imatinib mesylate twice daily. Imatinib mesylate treatment repeats every 4 weeks for up to 13 courses in the absence of disease progression or unacceptable toxicity. (Closed to accrual as of 5/28/04.)
- Stratum II A (recurrent or refractory high-grade intracranial gliomas/no concurrent EIACDs): Patients receive imatinib mesylate as in stratum I. (Closed to accrual as of 8/15/03.)
- Stratum II B (recurrent or refractory high-grade intracranial gliomas and concurrent EIACDs): Patients receive imatinib mesylate as in stratum I. (Closed to accrual as of 8/15/04.)
Cohorts of 2-3 patients receive escalating doses of imatinib mesylate until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which it is estimated that 20% of patients will experience dose-limiting toxicity. MTDs are independently estimated in each strata. For stratum I, newly diagnosed brain stem gliomas, the dose level which at least 5 of 6 patients experience no dose-limiting toxicity will be the dose used in the efficacy and safety phase (phase II).
Phase II: (Open to accrual as of 5/28/04.)
- Stratum I only: Patients undergo radiotherapy as in phase I. Patients receive imatinib mesylate at the MTD established in phase I.
Patients enrolled in the phase I portion and not treated at the MTD are to be followed for the shortest of 1) three months after the last protocol based treatment or 2) the date other therapy is initiated. Stratum I patients treated at the MTD in the phase I portion and all patients in the phase II portion of the study are to be followed until death or withdrawal from the study
PROJECTED ACCRUAL: Approximately 140 patients will be accrued for this study within 2 years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94143
- UCSF Comprehensive Cancer Center
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010-2970
- Children's National Medical Center
-
-
Illinois
-
Chicago, Illinois, United States, 60614
- Children's Memorial Hospital - Chicago
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke Comprehensive Cancer Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104-4318
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, United States, 15213
- Children's Hospital of Pittsburgh
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105-2794
- St. Jude Children's Research Hospital
-
-
Texas
-
Houston, Texas, United States, 77030-2399
- Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital
-
-
Washington
-
Seattle, Washington, United States, 98105
- Children's Hospital and Regional Medical Center - Seattle
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Age 3 to 21
- Performance status of Karnofsky 50-100% OR Lansky 50-100%
- Absolute neutrophil count greater than 1,000/mm3
- Platelet count greater than 100,000/mm3 (transfusion independent)
- Hemoglobin greater than 8 g/dL (transfusion allowed)
- Bilirubin no greater than 1.5 times normal for age
- SGPT less than 3 times normal for age
- Albumin at least 2 g/dL
- Creatinine less than 1.5 times normal for age OR Glomerular filtration rate greater than 70 mL/min
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective barrier contraception during and for 6 months after study participation
Stratum I
- Newly diagnosed diffuse intrinsic brainstem malignant glioma
- No disseminated disease
- No radiographic evidence of intratumoral hemorrhage before or during radiotherapy
- No prior chemotherapy (beyond routine corticosteroids)
- No prior irradiation
- Must not be receiving enzyme-inducing anticonvulsant drugs
Stratum II
- Histologically confirmed recurrent or refractory anaplastic astrocytoma, glioblastoma multiforme, or other high-grade glioma (including recurrent brain stem glioma
- No intratumoral hemorrhage unrelated to prior surgical procedure
- No myelosuppressive chemotherapy within 3 weeks (6 weeks if a nitrosourea agent) of study entry
- No prior imatinib mesylate
- At least 3 months since prior craniospinal radiotherapy (18 Gy or more)
- At least 8 weeks since prior local radiotherapy to primary tumor
- At least 2 weeks since prior focal radiotherapy for symptomatic
- At least 3 months since prior bone marrow transplantation
- Neurological deficits allowed if stable for at least 1 week prior to study
Exclusion Criteria
- Receiving other anticancer or experimental drug therapy.
- Ongoing uncontrolled infection.
- Significant cardiac, hepatic, gastrointestinal, renal, pulmonary, or psychiatric disease.
- Deep venous or arterial thrombosis within 6 weeks of registration.
- Taking warfarin.
- Newly diagnosed diffuse intrinsic brainstem malignant glioma with disseminated disease (stratum I)
- Intratumoral hemorrhage
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Imatinib mesylate
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants in Phase I Stratum I With Dose Limiting Toxicities (DLT) Observed During First 8 Weeks (Courses 1 and 2) of Imatinib Therapy
Time Frame: Day 1 of Imatinib Mesylate Therapy to Week 8
|
The dose limiting toxicity (DLT) analysis population consists of phase I stratum I participants who developed DLT during the maximum tolerated dose (MTD) estimation period (course 1 and 2) or who completed the MTD estimation period (courses 1 and 2) without DLTs.
DLTs observed during courses 1 and 2 were used to estimate the MTD.
The estimated MTD based on the 23 participants who either had a DLT during course 1 or 2 or completed courses 1 and 2 without DLT is 265 mg/m2/day.
|
Day 1 of Imatinib Mesylate Therapy to Week 8
|
Number of Participants in Phase I Stratum II With Dose Limiting Toxicities (DLT) Observed During First 8 Weeks (Courses 1 and 2) of Imatinib Therapy
Time Frame: Day 1 of Imatinib Mesylate Therapy to Week 8
|
The dose limiting toxicity (DLT) analysis population consisted of phase I stratum II participants who developed DLT during the maximum tolerated dose (MTD) estimation period (courses 1 and 2) or who completed the MTD estimation period (courses 1 and 2) without DLTs.
DLTs observed during courses 1 and 2 were used to estimate the MTD.
The estimated MTD based on the DLT analysis population of 20 in stratum IIA was 465 mg/m2/day.
An MTD was not established in stratum IIB as no DLTs were observed at the higher dose levels of 620 and 800 mg/m2/day.
|
Day 1 of Imatinib Mesylate Therapy to Week 8
|
Median Progression-free Survival (PFS)
Time Frame: Assessed pre-radiation, before the first dose of imatinib, and then every 8 weeks
|
Progression-free survival is defined as the interval from initiation of treatment to the earliest of disease progression (tumor increase of 25% over baseline tumor measurement; appearance of new lesion(s); or progressive/worsening neurological status) or death for patients who failed, or to the last date of follow up for patients without failure.
|
Assessed pre-radiation, before the first dose of imatinib, and then every 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Volume FLAIR at Two Weeks After Completion of Radiation
Time Frame: Baseline and two weeks post completion of radiation
|
This study attempted to investigate in an exploratory manner the effect of radiation (RT) on changes in various neuroimaging variables in pediatric brainstem gliomas (stratum I).
Neuroimaging changes may have some association with outcome (response, survival, etc.).
Volume FLAIR is one parameter obtained from standard magnetic resonance imaging (MRI) studies of the brain.
Volume FLAIR was obtained at baseline (pre-radiation) and within two (+/- one) weeks after completion of RT.
|
Baseline and two weeks post completion of radiation
|
Peak Concentration (Cmax)
Time Frame: Day 1 of Course 1
|
Peak concentration (cmax) is a pharmacokinetic measure defined as the highest concentration of a drug measured after the drug is administered.
The cmax of imatinib mesylate on day 1 of course 1 is reported.
Two milliliter (0.5 ml for children under the age of 5) blood samples were collected immediately prior to imatinib mesylate administration on Day 1 of Course 1 and at the following timepoints following drug administration: 0.5, 1, 1.5, 2, 4, 10 and 12 hours after the morning dose.
|
Day 1 of Course 1
|
Median Overall Survival
Time Frame: Assessed before radiation therapy, before the first dose of imatinib, then every 8 weeks.
|
Overall Survival (OS) is defined as the interval from initiation of treatment to death or date of last contact for surviving patients.
|
Assessed before radiation therapy, before the first dose of imatinib, then every 8 weeks.
|
Pre-treatment Basic Fibroblast Growth Factor Values From Urine
Time Frame: Pre-treatment
|
This study attempted to investigate in an exploratory manner the effect of biological markers on tumor growth.
Basic fibroblast growth factor (bFGF) may play a role in tumor development by helping tumor vessels establish and grow.
Urine was collected from participants before treatment to measure the baseline urine bFGF values.
|
Pre-treatment
|
Pre-treatment Basic Fibroblast Growth Factor Values From Plasma
Time Frame: Pre-treatment
|
This study attempted to investigate in an exploratory manner the effect of biological markers on tumor growth.
Basic fibroblast growth factor (bFGF) may play a role in tumor development by helping tumor vessels establish and grow.
Blood (plasma) was drawn from participants before treatment to measure the baseline plasma bFGF values.
|
Pre-treatment
|
Pre-treatment Vascular Endothelial Growth Factor From Urine
Time Frame: Pre-treatment
|
This study attempted to investigate in an exploratory manner the effect of biological markers on tumor growth.
Vascular endothelial growth factor (VEGF) may play a role in tumor development by helping tumor vessels establish and grow.
Urine was collected from participants before treatment to measure the baseline urine VEGF values.
|
Pre-treatment
|
Pre-treatment Vascular Endothelial Growth Factor Values From Plasma
Time Frame: Pre-treatment
|
This study attempted to investigate in an exploratory manner the effect of biological markers on tumor growth.
Vascular endothelial growth factor (VEGF) may play a role in tumor development by helping tumor vessels establish and grow.
Blood (plasma) was drawn from participants before treatment to measure the baseline plasma VEGF values.
|
Pre-treatment
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Williams G, Fahey FH, Treves ST, Kocak M, Pollack IF, Boyett JM, Kun LE, Poussaint TY. Exploratory evaluation of two-dimensional and three-dimensional methods of FDG PET quantification in pediatric anaplastic astrocytoma: a report from the Pediatric Brain Tumor Consortium (PBTC). Eur J Nucl Med Mol Imaging. 2008 Sep;35(9):1651-8. doi: 10.1007/s00259-008-0780-7. Epub 2008 Apr 19.
- Pollack IF, Jakacki RI, Blaney SM, Hancock ML, Kieran MW, Phillips P, Kun LE, Friedman H, Packer R, Banerjee A, Geyer JR, Goldman S, Poussaint TY, Krasin MJ, Wang Y, Hayes M, Murgo A, Weiner S, Boyett JM. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol. 2007 Apr;9(2):145-60. doi: 10.1215/15228517-2006-031. Epub 2007 Feb 9.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioma
- Nervous System Neoplasms
- Central Nervous System Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Imatinib Mesylate
Other Study ID Numbers
- NCI-2012-03019
- U01CA081457 (U.S. NIH Grant/Contract)
- PBTC-006 (Other Identifier: Pediatric Brain Tumor Consortium Protocol Identifier)
- CDR0000068761 (Registry Identifier: PDQ (Physician Data Query))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain and Central Nervous System Tumors
-
Children's Hospital Los AngelesUnknownBrain and Central Nervous System TumorsUnited States, Canada, Australia, Switzerland, New Zealand
-
Emory UniversityNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Abramson Cancer Center of the University of PennsylvaniaNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Duke UniversityNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Duke UniversityNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
St. Jude Children's Research HospitalCompletedBrain Tumors | Central Nervous System TumorsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedBrain Tumors | Central Nervous System TumorsUnited States, Australia, Canada
-
University of Colorado, DenverNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Pediatric Brain Tumor ConsortiumNational Cancer Institute (NCI)CompletedVNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain TumorsBrain and Central Nervous System TumorsUnited States
-
National Cancer Institute (NCI)CompletedBrain and Central Nervous System Tumors
Clinical Trials on imatinib mesylate
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.CompletedChronic Myeloid LeukemiaChina
-
Scandinavian Sarcoma GroupCompleted
-
Institut BergoniéNovartisTerminatedLeukemia, Myeloid, Chronic-PhaseFrance
-
Sarit AssoulineNovartisRecruitingChronic Myeloid Leukemia | Chronic Myeloid Leukemia in Remission | Chronic Myeloid Leukemia, BCR/ABL-PositiveCanada
-
University Health Network, TorontoNational Cancer Institute (NCI)CompletedHead and Neck CancerUnited States, Canada
-
NovartisCompletedLeukemiaUnited States
-
National Cancer Institute (NCI)CompletedSarcoma | Childhood Malignant Fibrous Histiocytoma of BoneUnited States
-
European Organisation for Research and Treatment...CompletedSarcoma | Small Intestine Cancer | Ovarian Cancer | Endometrial Cancer | Gastrointestinal Stromal TumorFrance, Denmark, Netherlands, Belgium, United Kingdom
-
Poitiers University HospitalNovartis; Roche Pharma AG; Ministry of Health, FranceCompleted
-
European Organisation for Research and Treatment...UNICANCER; Grupo Espanol de Investigacion en Sarcomas; Italian Sarcoma GroupCompletedGastrointestinal Stromal TumorFrance, Australia, United Kingdom, Germany, Denmark, Spain